Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.